retrogenix cell microarray technology (Charles River Laboratories)
86
Structured Review
Charles River Laboratories
retrogenix cell microarray technology
Retrogenix Cell Microarray Technology, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/retrogenix+cell+microarray+technology/cell+microarray+screen+technology/pmc12977278-382-14-18
Average 86 stars, based on 1 article reviews
Retrogenix Cell Microarray Technology, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/retrogenix+cell+microarray+technology/cell+microarray+screen+technology/pmc12977278-382-14-18
Average 86 stars, based on 1 article reviews
retrogenix cell microarray technology - by Bioz Stars,
2026-11
86/100 stars
Images
Related Articles
Microarray:Article Title: Preclinical assessment of broadly neutralizing HIV-1 antibody BNT351 with optimized pharmacokinetics and potent antiviral activity Article Snippet: Briefly, modified sensor chips were coated with an avidin variant, followed by reversible immobilization of biotin-containing human FcRs (Acro Biosystems) or SOSIP Env trimer, which were injected at 2–5 μL/min until the aspired surface density was reached. .. The Article Title: Characterization of JNJ-80948543 a novel CD79bxCD20xCD3 trispecific antibody for B-cell non-Hodgkin lymphoma. Article Snippet: .. Each binding arm of JNJ-80948543 was evaluated for binding specificity in the Retrogenix® Article Title: Preclinical assessment of broadly neutralizing HIV-1 antibody BNT351 with optimized pharmacokinetics and potent antiviral activity Article Snippet: .. The Article Title: Characterization of JNJ-80948543 a novel CD79bxCD20xCD3 trispecific antibody for B-cell non-Hodgkin lymphoma. Article Snippet: .. The individual CD79b, CD20 and CD3 molecules were screened for binding specificity using the Retrogenix® Article Title: CHS-114: an afucosylated anti-CCR8 monoclonal antibody that selectively depletes intratumoral Treg cells and induces antitumor immune responses Article Snippet: .. Screening for off-target binding of Article Title: Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models Article Snippet: For all in vivo studies, female nonobese diabetic (NOD) severe combined immunodeficiency (scid) gamma (NSG; The Jackson Laboratory) mice aged ∼5 to 8 weeks and weighing ∼20 g were used. .. The binding specificity of the individual BCMA and GPRC5D antibodies were assessed using the Retrogenix Clinical Proteomics:Article Title: Preclinical assessment of broadly neutralizing HIV-1 antibody BNT351 with optimized pharmacokinetics and potent antiviral activity Article Snippet: Briefly, modified sensor chips were coated with an avidin variant, followed by reversible immobilization of biotin-containing human FcRs (Acro Biosystems) or SOSIP Env trimer, which were injected at 2–5 μL/min until the aspired surface density was reached. .. The Article Title: Preclinical assessment of broadly neutralizing HIV-1 antibody BNT351 with optimized pharmacokinetics and potent antiviral activity Article Snippet: .. The Membrane:Article Title: Preclinical assessment of broadly neutralizing HIV-1 antibody BNT351 with optimized pharmacokinetics and potent antiviral activity Article Snippet: Briefly, modified sensor chips were coated with an avidin variant, followed by reversible immobilization of biotin-containing human FcRs (Acro Biosystems) or SOSIP Env trimer, which were injected at 2–5 μL/min until the aspired surface density was reached. .. The Article Title: Preclinical assessment of broadly neutralizing HIV-1 antibody BNT351 with optimized pharmacokinetics and potent antiviral activity Article Snippet: .. The Binding Assay:Article Title: Characterization of JNJ-80948543 a novel CD79bxCD20xCD3 trispecific antibody for B-cell non-Hodgkin lymphoma. Article Snippet: .. Each binding arm of JNJ-80948543 was evaluated for binding specificity in the Retrogenix® Article Title: Characterization of JNJ-80948543 a novel CD79bxCD20xCD3 trispecific antibody for B-cell non-Hodgkin lymphoma. Article Snippet: .. The individual CD79b, CD20 and CD3 molecules were screened for binding specificity using the Retrogenix® Article Title: CHS-114: an afucosylated anti-CCR8 monoclonal antibody that selectively depletes intratumoral Treg cells and induces antitumor immune responses Article Snippet: .. Importantly, as specificity can often be challenging for antibodies against GPCRs, a Article Title: CHS-114: an afucosylated anti-CCR8 monoclonal antibody that selectively depletes intratumoral Treg cells and induces antitumor immune responses Article Snippet: .. Screening for off-target binding of Article Title: Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models Article Snippet: For all in vivo studies, female nonobese diabetic (NOD) severe combined immunodeficiency (scid) gamma (NSG; The Jackson Laboratory) mice aged ∼5 to 8 weeks and weighing ∼20 g were used. .. The binding specificity of the individual BCMA and GPRC5D antibodies were assessed using the Retrogenix other:Article Title: Overcoming claudin family homology: discovery of ARC101, a highly potent CLDN6-specific T-cell engager with a novel CD3 binder for ovarian adenocarcinoma Article Snippet: MFI values were extracted, background-subtracted using secondary antibody control wells, and plotted in Prism (GraphPad, version 10.4) using a four-parameter nonlinear regression. |